The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer

International Journal of Pharmaceutics

Volumn 484, Issue 1-2, 2015, Pages 16-28

  Wan, Xu ^a   Zheng, Xiaoyao ^a   Pang, Xiaoying ^a   Zhang, Zheming ^a   Jing, Tao ^b   Xu, Wei ^b   Zhang, Qizhi ^a  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Zhangjiang Medicine Valley Public Service Platform Co Ltd   (China)

Author keywords

4T1 cells; HSA nanoparticle; Lapatinib; Triple negative breast cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HUMAN SERUM ALBUMIN; LAPATINIB; ANTINEOPLASTIC AGENT; NANOPARTICLE; QUINAZOLINE DERIVATIVE; SERUM ALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; BREAST CANCER; CELL CYCLE; CELL CYCLE ARREST; CONTROLLED STUDY; CYTOTOXICITY ASSAY; EXTRACELLULAR MATRIX; FEMALE; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TRANSMISSION ELECTRON MICROSCOPY; TRIPLE NEGATIVE BREAST CANCER; X RAY PHOTOELECTRON SPECTROSCOPY; ANIMAL; BAGG ALBINO MOUSE; DRUG SCREENING; HUMAN; METABOLISM; NUDE MOUSE; PROCEDURES; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; QUINAZOLINES; SERUM ALBUMIN; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923363133     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.02.037     Document Type: Article

References (32)

1. A. Albanese, P.S. Tang, and W.C. Chan The effect of nanoparticle size, shape, and surface chemistry on biological systems Annu. Rev. Biomed. Eng. 14 2012 1 16
2. C.J. Aslakson, and F.R. Miller Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor Cancer Res. 52 1992 1399 1405
3. F. Bai, B.R. Freeman, C.H. Fraga, M. Fouladi, and C.F. Stewart Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS) J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 831 2006 169 175
4. K.R. Bauer, M. Brown, R.D. Cress, C.A. Parise, and V. Caggiano Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry Cancer 109 2007 1721 1728
5. N.R. Budha, A. Frymoyer, G.S. Smelick, J.Y. Jin, M.R. Yago, and M.J. Dresser Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin. Pharmacol. Ther. 92 2012 203 213
6. H.R. Burris, C.W. Taylor, S.F. Jones, K.M. Koch, M.J. Versola, and N. Arya A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies Clin. Cancer Res. 15 2009 6702 6708
7. L.C. Collins, A. Martyniak, M.J. Kandel, Z.K. Stadler, S. Masciari, and A. Miron Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers Am. J. Surg. Pathol. 33 2009 1093 1097
8. D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, and A. Santoro Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N. Engl. J. Med. 351 2004 337 345
9. N. Desai, V. Trieu, Z. Yao, L. Louie, S. Ci, and A. Yang Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel Clin. Cancer Res. 12 2006 1317 1324
10. A.O. Elzoghby, W.M. Samy, and N.A. Elgindy Albumin-based nanoparticles as potential controlled release drug delivery systems J. Control. Release 157 2012 168 182
11. B. Gumuskaya, M. Alper, S. Hucumenoglu, K. Altundag, A. Uner, and G. Guler EGFR expression and gene copy number in triple-negative breast carcinoma Cancer Genet. Cytogenet. 203 2010 222 229
12. W. Gunther, E. Pawlak, R. Damasceno, H. Arnold, and A.J. Terzis Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids Br. J. Cancer 88 2003 463 469
13. B.G. Haffty, Q. Yang, M. Reiss, T. Kearney, S.A. Higgins, and J. Weidhaas Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer J. Clin. Oncol. 24 2006 5652 5657
14. R.K. Jain, and T. Stylianopoulos Delivering nanomedicine to solid tumors Nat. Rev. Clin. Oncol. 7 2010 653 664
15. P. Kaur, G.M. Nagaraja, H. Zheng, D. Gizachew, M. Galukande, and S. Krishnan A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease BMC Cancer 12 2012 120
16. F. Kratz Albumin as a drug carrier: design of prodrugs: drug conjugates and nanoparticles J. Control. Release 132 2008 171 183
17. V. Martin, F. Botta, E. Zanellato, F. Molinari, S. Crippa, and L. Mazzucchelli Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features Histol. Histopathol. 27 2012 785 792
18. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392
19. P.J. Medina, and S. Goodin Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases Clin. Ther. 30 2008 1426 1447
20. Z. Mi, H. Guo, P.Y. Wai, C. Gao, J. Wei, and P.C. Kuo Differential osteopontin expression in phenotypically distinct subclones of murine breast cancer cells mediates metastatic behavior J. Biol. Chem. 279 2004 46659 46667
21. H. Nakajima, Y. Ishikawa, M. Furuya, T. Sano, Y. Ohno, and J. Horiguchi Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer Breast Cancer 21 2014 66 74
22. T.O. Nielsen, F.D. Hsu, K. Jensen, M. Cheang, G. Karaca, and Z. Hu Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin. Cancer Res. 10 2004 5367 5374
23. H.S. Park, M.H. Jang, E.J. Kim, H.J. Kim, H. Lee, and Y.J. Kim High EGFR gene copy number predicts poor outcome in triple-negative breast cancer Mod. Pathol. 27 2014 1212 1222
24. B.A. Pulaski, and S. Ostrand-Rosenberg Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines Cancer Res. 58 1998 1486 1493
25. J.S. Reis-Filho, C. Pinheiro, M.B. Lambros, F. Milanezi, S. Carvalho, and K. Savage EGFR amplification and lack of activating mutations in metaplastic breast carcinomas J. Pathol. 209 2006 445 453
26. S. Sebak, M. Mirzaei, M. Malhotra, A. Kulamarva, and S. Prakash Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis Int. J. Nanomed. 5 2010 525 532
27. B.W. Stewart, and C.P. Wild World Cancer Report 2014 2014 World Health Organization
28. D.S. Tan, C. Marchio, R.L. Jones, K. Savage, I.E. Smith, and M. Dowsett Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients Breast Cancer Res. Treat. 111 2008 27 44
29. K. Tao, M. Fang, J. Alroy, and G.G. Sahagian Imagable 4T1 model for the study of late stage breast cancer BMC Cancer 8 2008 228
30. A.J. Tevaarwerk, and J.M. Kolesar Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer Clin. Ther. 31 Pt 2 2009 2332 2348
31. W. Xia, R.J. Mullin, B.R. Keith, L. Liu, H. Ma, and D.W. Rusnak Anti-tumor activity of GW57: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways Oncogene 21 2002 6255 6263
32. B. Zhang, H. Wang, Z. Liao, Y. Wang, Y. Hu, and J. Yang EGFP-EGF1-conjugated nanoparticles for targeting both neovascular and glioma cells in therapy of brain glioma Biomaterials 35 2014 4133 4145